Dogwood Therapeutics DWTX Business Segments — Interest Income Expense Net

Similar metrics at other companies

IMNMSingle Reportable — Interest Income Expense Net

$5.49M+83.3%

VERXSingle Reportable — Interest Income Expense Net

-$957K+37.8%

EWTXSingle Reportable — Interest Income Expense Nonoperating Net

$5.1M-1.1%

CZNCSingle Reportable — Interest Income Expense Net

$28.45M+42.4%

NSSCSingle Reportable — Interest Income Expense Nonoperating Net

$986K+14.4%

NEC

NECBSingle Reportable — Interest Income Expense Net

$24.13M-0.5%

Questions, answered.

What is Dogwood Therapeutics's business segments — interest income expense net?

Dogwood Therapeutics (DWTX) reported business segments — interest income expense net of $77.35K in Q1 2026.

How has Dogwood Therapeutics's business segments — interest income expense net changed year-over-year?

Dogwood Therapeutics's business segments — interest income expense net increased by 152.6% year-over-year, from -$147.09K to $77.35K.

What is the long-term trend for Dogwood Therapeutics's business segments — interest income expense net?

Over 2 years (2023 to 2025), Dogwood Therapeutics's business segments — interest income expense net has grown at a 14.3% compound annual growth rate (CAGR), from $150.9K to -$197.24K.

What does business segments — interest income expense net mean?

This metric represents the net balance of interest income earned on cash equivalents and investments minus interest expenses incurred on debt obligations. For a development-stage biotechnology company, it reflects the efficiency of treasury management and the cost of capital used to fund ongoing research activities.